Foghorn Therapeutics Appoints New CMO, Discloses Officer Compensation
Ticker: FHTX · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $475,000, $87,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel, compensation
Related Tickers: FHTX
TL;DR
Foghorn Therapeutics swapped CMOs and detailed exec pay. New guy is Dr. Allen, old guy is Dr. Law.
AI Summary
Foghorn Therapeutics Inc. announced on April 16, 2024, the appointment of Dr. Jeffrey W. Allen as Chief Medical Officer and the departure of Dr. Adrian S. Law as Chief Medical Officer. The company also disclosed compensatory arrangements for its officers.
Why It Matters
Changes in key executive positions like the Chief Medical Officer can signal shifts in the company's strategic direction and drug development pipeline.
Risk Assessment
Risk Level: medium — Executive changes, especially in critical roles like CMO, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- Dr. Jeffrey W. Allen (person) — Appointed Chief Medical Officer
- Dr. Adrian S. Law (person) — Departed Chief Medical Officer
- April 16, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new Chief Medical Officer of Foghorn Therapeutics?
Dr. Jeffrey W. Allen has been appointed as the new Chief Medical Officer.
Who previously held the position of Chief Medical Officer at Foghorn Therapeutics?
Dr. Adrian S. Law previously held the position of Chief Medical Officer.
What is the exact date of this Form 8-K filing?
The exact date of this Form 8-K filing is April 16, 2024.
What other information is disclosed in this filing besides executive changes?
The filing also discloses compensatory arrangements of certain officers.
In which state is Foghorn Therapeutics incorporated?
Foghorn Therapeutics is incorporated in Delaware.
Filing Stats: 987 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-04-16 07:01:54
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
- $475,000 — ovides for (i) an annual base salary of $475,000, (ii) eligibility to receive an annual
- $87,000 — arget Bonus"), (iii) a signing bonus of $87,000, less required deductions and withholdi
Filing Documents
- fhtx-20240416.htm (8-K) — 38KB
- ex101foghornemploymentagre.htm (EX-10.1) — 50KB
- ex991cfoappointment.htm (EX-99.1) — 15KB
- image_0.jpg (GRAPHIC) — 63KB
- 0001628280-24-016281.txt ( ) — 334KB
- fhtx-20240416.xsd (EX-101.SCH) — 2KB
- fhtx-20240416_lab.xml (EX-101.LAB) — 22KB
- fhtx-20240416_pre.xml (EX-101.PRE) — 13KB
- fhtx-20240416_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On April 16, 2024, the Company issued a press release announcing the foregoing management changes. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 10.1 Letter Agreement between Foghorn Therapeutics Inc. and Kristi an F. Hu mer , dated April 16, 2024 99.1 Press release issued on April 16 , 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael J. LaCascia Michael J. LaCascia Chief Legal Officer Date: April 16, 2024